Pseudocirrhosis is a diffuse nodularity of the liver that radiologically mimics cirrhosis but is a distinct pathological process. It is seen almost exclusively in patients with liver metastases and may represent a response to systemic treatment. Data on the risk factors for pseudocirrhosis and outcomes are limited. In total, 170 patients with a diagnosis of breast cancer and pseudocirrhosis in a 10-year period were identified and retrospectively analysed. Data were collected on baseline patient characteristics, treatments received, and outcomes. Median time between diagnosis of liver metastases and diagnosis of pseudocirrhosis was 17.1 months (range, 0–149 months). In total, 89.4% of patients received chemotherapy between their diagnosis of breast cancer liver metastases and their diagnosis of pseudocirrhosis, most commonly a taxane (74.7%) or capecitabine (67.1%), and the median treatment lines received was 3. Median OS from first diagnosis of pseudocirrhosis was 7.6 months (95% CI: 6.1–9.6 months) and was longer in patients with HER2+ disease at 16.7 months (95% CI: 6.4–32.9 months), which was statistically significant. In our study, pseudocirrhosis occurred in the presence of liver metastases and was associated with a poor prognosis. HER2+ patients with pseudocirrhosis had a better prognosis than other subtypes, but we did not identify other significant predictors of survival. Chemotherapy was not a prerequisite for pseudocirrhosis development, although the majority of patients had received at least one line of chemotherapy before pseudocirrhosis was diagnosed.
假性肝硬化是一种肝脏弥漫性结节性病变，其影像学表现与肝硬化相似，但属于独特的病理过程。该病症几乎仅见于肝转移患者，可能代表对全身治疗的反应。目前关于假性肝硬化危险因素及预后的数据有限。本研究共纳入170例在十年间确诊为乳腺癌伴假性肝硬化的患者进行回顾性分析。收集的数据包括患者基线特征、接受的治疗方案及临床结局。从肝转移确诊至假性肝硬化诊断的中位时间为17.1个月（范围：0-149个月）。在乳腺癌肝转移确诊至假性肝硬化诊断期间，共有89.4%的患者接受过化疗，最常用方案为紫杉烷类（74.7%）或卡培他滨（67.1%），接受治疗的中位线数为3线。自首次确诊假性肝硬化起的中位总生存期为7.6个月（95% CI：6.1-9.6个月），其中HER2阳性患者生存期更长达16.7个月（95% CI：6.4-32.9个月），该差异具有统计学意义。本研究表明，假性肝硬化发生于肝转移背景下且预后不良。HER2阳性假性肝硬化患者较其他亚型预后更佳，但未发现其他显著生存预测因素。虽然多数患者在确诊假性肝硬化前至少接受过一线化疗，但化疗并非假性肝硬化发生的必要条件。
The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer
肿瘤(癌症)患者之家